Test standard prostate cancer treatment with or without targeted spot radiation
Part of Cancer, Kidney & urinary clinical trials.
This study tests whether adding targeted local treatment (like radiation to a few spots seen on scans) improves outcomes for some people with limited (oligometastatic) prostate cancer. It compares standard systemic therapy alone versus standard therapy plus PET-scan–guided spot treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and can sign the study consent form.
- Your prostate cancer is confirmed by biopsy results (tissue or cells) and is metastatic or recurring in a limited way.
- Your overall health is limited but still able to function (ECOG score 2).
- You have scans (CT/MRI and specific prostate/bone scans) showing 1–10 suspicious spots, and your doctor plans imaging/testing to map them.
- You are taking (or starting) systemic prostate cancer therapy, and PSA levels suggest recurrence under specific lab patterns.
- You have had (or have planned) NGS testing on your tumor (a genetic test of the cancer).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special PET scan (POSLUMA) before and after radiation to see if it helps treat prostate cancer that has spread to a few spots outside the pelvis. It's for men whose cancer still responds to hormone therapy and who have not had widespread spread.
This Phase 2 trial tests a radiation-focused approach for people with newly diagnosed (de novo) prostate cancer that has spread to a small number of spots, especially in bone. It aims to see how well the treatment controls the cancer while keeping side effects manageable.
This Phase 3 trial tests whether treating only a small number of prostate cancer metastases can help people with “oligorecurrent” (limited repeat) prostate cancer. It may reduce cancer activity while avoiding broader whole-body treatment for some patients.
This trial is testing whether giving radiation to all spots of cancer that show up on a PSMA PET scan works better than giving radiation only to the main tumor in the prostate. It is for men whose prostate cancer has spread to a few other places (up to 10 spots).
This trial tests whether adding a PSMA-targeted radioactive medicine (Lu-PSMA) to focused stereotactic radiation to a few prostate cancer spots works better than radiation alone. It may help people with limited, asymptomatic spread of prostate cancer by improving cancer control while carefully monitoring side effects.
This trial tests whether using a specialized PSMA PET scan to guide radiation can better treat prostate cancer that returns after prostate surgery. It targets the “prostate bed” area with a shorter, stronger radiation schedule (hypofractionated) to control rising PSA levels.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.